Genenta to present updated Phase I/II data at upcoming scientific congresses SNO and ASH
MILAN (Italy)/NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno- gene therapy for cancer (Temferon™), announced today that it will be presenting updated preliminary Phase I/II clinical data on Temferon at two upcoming scientific congresses.
The Society for Neuro-Oncology (SNO) 2021 Annual Meeting and Education Day, November 18-21, Boston, USA
Title: TEM-GBM: A Phase I-IIa Dose-Escalation Study Delivering IFN-Α within Glioblastoma Multiforme Tumor Microenvironment by Genetically Modified TIE-2 Expressing Monocytes
Type: Poster presentation
Time: Friday November 19, 2021, 7.30 PM – 9.30 PM ET
63rd American Society of Hematology (ASH) Annual Meeting and Exposition 2021, December 11-14, Atlanta, USA and virtual
Title: TEM-GBM: An Open-Label, Phase I/IIa Dose-Escalation Study Evaluating the Safety and Efficacy of Genetically Modified Tie-2 Expressing Monocytes to Deliver IFN- α within Glioblastoma Tumor Microenvironment Type: Poster presentation
Day: Sunday December 12, 2021, 6 PM – 8 PM ET